In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baked-In Goodness: Shire Buys New River for $2.6 Billion

Executive Summary

Shire's $2.6 billion all-cash acquisition of its Vyvanse partner New River Pharmaceuticals is no surprise. The original deal signed by the companies in 2005 engineered Shire's motivation to buy New River in the event Vyvanse became a success. New River's unusually consolidated ownership allowed it to remain independent until the eve of Vyvanse's approval and secure a top-drawer takeout valuation.
Advertisement

Related Content

Supernus Aims For IPO Backed By Unusual Royalty Deal
Deal Statistics Quarterly, Q1 2007
Deal Statistics Quarterly, Q1 2007
Share the Wealth? No Thanks
Share the Wealth? No Thanks
Generic Plavix: As Bristol Swoons, Broad Implications
Generic Plavix: As Bristol Swoons, Broad Implications
The Price is Wrong: Finding Alternatives to Traditional IPOs
Shire: Remodeling Specialty Pharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel